Elicio Therapeutics (ELTX) vs Zhengye Biotechnology (ZYBT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Zhengye Biotechnology (ZYBT) has outperformed Elicio Therapeutics (ELTX) over the past year, losing 62.7% versus a loss of 82.8%. Zhengye Biotechnology is the larger company by market cap ($55.0 million vs $48.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELTX | ZYBT |
|---|---|---|
| Share price | $1.85 | $1.16 |
| Market cap | $48.49M | $54.97M |
| 1-day change | +1.93% | +0.88% |
| YTD return | -77.26% | -0.01% |
| 1-year return | -82.79% | -62.67% |
| 5-year return | -97.92% | — |
| EPS (TTM) | $-2.16 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.00 | $8.01 |
| 52-week low | $1.71 | $0.616 |
| Distance from 52-week high | -88.47% | -85.52% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +640.92% | — |
| Average volume | 340.72K | 5.10M |
| Shares outstanding | 26.28M | 47.39M |
| Employees | 33 | 269 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZYBT has outperformed ELTX by 20.1 percentage points over the past year.
About Elicio Therapeutics
ELTX stock →Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About Zhengye Biotechnology
ZYBT stock →Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Health Care · Biotechnology: Pharmaceutical Preparations · 269 employees
ELTX vs ZYBT FAQ
Which is bigger, Elicio Therapeutics or Zhengye Biotechnology?
Zhengye Biotechnology (ZYBT) is larger, with a market capitalization of $54.97M compared with $48.49M for Elicio Therapeutics (ELTX).
Which stock has performed better over the past year, ELTX or ZYBT?
ZYBT returned -62.67% over the past 12 months, compared with -82.79% for ELTX (price return, excluding dividends). Past performance does not predict future results.
Are Elicio Therapeutics and Zhengye Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.